SCHEMBL29672885

SCHEMBL29672885

N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CS)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ IL23R Q5VWK5 16/20 0.57
▸ C5AR1 P21730 1/20 0.55
▸ TUBB4A P04350 1/20 0.54
▸ TUBB P07437 1/20 0.54
▸ TUBA3C P0DPH7 1/20 0.54
▸ TUBA1B P68363 1/20 0.54
▸ TUBA4A P68366 1/20 0.54
▸ TUBB4B P68371 1/20 0.54
▸ TUBB3 Q13509 1/20 0.54
▸ TUBB2A Q13885 1/20 0.54
▸ TUBB8 Q3ZCM7 1/20 0.54
▸ TUBA3E Q6PEY2 1/20 0.54
▸ TUBA1A Q71U36 1/20 0.54
▸ TUBA1C Q9BQE3 1/20 0.54
▸ TUBB6 Q9BUF5 1/20 0.54
▸ TUBB2B Q9BVA1 1/20 0.54
▸ TUBB1 Q9H4B7 1/20 0.54
▸ UTS2R Q9UKP6 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30463394 1.00 IL23R (0.57) IL23RC5AR1TUBB4ATUBBTUBA3C
SCHEMBL29540710 0.96 C5AR1 (0.58) IL23RC5AR1TUBB4ATUBBTUBA3C
SCHEMBL29641170 0.94 TUBB4A (0.57) IL23RC5AR1TUBB4ATUBBTUBA3C
SCHEMBL30132314 0.94 TUBB4A (0.57) IL23RC5AR1TUBB4ATUBBTUBA3C
SCHEMBL29883587 0.94 IL23R (0.61) IL23RC5AR1TUBB4ATUBBTUBA3C
SCHEMBL30592736 0.94 IL23R (0.62) IL23RUTS2R
SCHEMBL29461985 0.93 TUBB4A (0.58) IL23RC5AR1TUBB4ATUBBTUBA3C
SCHEMBL31680253 0.93 C5AR1 (0.61) C5AR1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29517075 0.93 C5AR1 (0.54) IL23RC5AR1TUBB4ATUBBTUBA3C
SCHEMBL31680254 0.92 C5AR1 (0.58) IL23RC5AR1TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4711005-A2 METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH Stealth BioTherapeutics Inc. (US) 2026-03-18 — — EP disclosed
US-20250276116-A1 METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION TUFTS MEDICAL CENTER, INC. 2025-09-04 — — US disclosed
US-20250263433-A1 METHODS FOR REDUCING CD36 EXPRESSION CORNELL RESEARCH FOUNDATION, INC. (US) 2025-08-21 — — US disclosed
US-20250255929-A1 METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH STEALTH BIOTHERAPEUTICS INC. (US) 2025-08-14 — — US disclosed
EP-4596049-A2 PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION Stealth BioTherapeutics Inc. (US) 2025-08-06 — — EP disclosed
US-12337023-B2 Methods and compositions for the prevention and treatment of disease STEALTH BIOTHERAPEUTICS INC. (US) 2025-06-24 — — US disclosed
US-20250161401-A1 METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY STEALTH BIOTHERAPEUTICS INC. (US) 2025-05-22 — — US disclosed
EP-4302829-B1 PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION STEALTH BIOTHERAPEUTICS INC (US) 2025-05-21 — — EP disclosed
EP-3603658-B1 PEPTIDE FOR USE IN THE TREATMENT OF HEART FAILURE RESULTING FROM HYPERTROPHIC CARDIOMYOPATHY UNIV CORNELL (US) 2025-01-08 — — EP disclosed
US-12102659-B2 Methods for the prevention or treatment of heart failure CORNELL UNIVERSITY (US) 2024-10-01 — — US disclosed
US-20230285499-A1 METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE CORNELL UNIVERSITY (US) 2023-09-14 — — US disclosed
EP-4233887-A1 METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Stealth BioTherapeutics Inc. (US) 2023-08-30 — — EP disclosed
US-20230149501-A1 METHODS FOR REDUCING OXIDATIVE DAMAGE CORNELL RESEARCH FOUNDATION, INC. (US) 2023-05-18 — — US disclosed
US-20230109564-A1 METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY STEALTH BIOTHERAPEUTICS INC. (US) 2023-04-06 — — US disclosed
US-20230043587-A1 METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASE STEALTH BIOTHERAPEUTICS INC. (US) 2023-02-09 — — US disclosed
EP-3513800-B1 AROMATIC-CATIONIC PEPTIDE FOR USE IN THE TREATMENT OF ANTIPHOSPHOLIPID SYNDROME UNIV CORNELL (US) 2022-12-07 — — EP disclosed
EP-4085920-A1 METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Stealth BioTherapeutics Inc. (US) 2022-11-09 — — EP disclosed
US-11376304-B2 Methods and compositions for the prevention and treatment of disease STEALTH BIOTHERAPEUTICS INC. (US) 2022-07-05 — — US disclosed
US-11366104-B2 Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening STEALTH BIOTHERAPEUTICS INC. (US) 2022-06-21 — — US disclosed
EP-4005582-A1 TREATMENT OF LEFT VENTRICULAR REMODELING Stealth BioTherapeutics Inc. (US) 2022-06-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285499-A1 METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE TNNI3, FABP3, TNNC1 IL23R 4061/4885C5AR1 1061/4885TUBB4A 2209/4885
US-20230043587-A1 METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASE COL2A1, ALPI, COL14A1 IL23R 1209/4885C5AR1 1277/4885TUBB4A 487/4885
US-20250255929-A1 METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH TNNI3, TNNT2, FABP3 IL23R 2859/4885C5AR1 1444/4885TUBB4A 1499/4885
US-12337023-B2 Methods and compositions for the prevention and treatment of disease COL2A1, ALPI, COL14A1 IL23R 1209/4885C5AR1 1277/4885TUBB4A 487/4885
US-20250161401-A1 METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY MTPN, UTRN, SMN1; SMN2 IL23R 4208/4885C5AR1 1000/4885TUBB4A 3495/4885
US-12102659-B2 Methods for the prevention or treatment of heart failure TNNI3, FABP3, TNNC1 IL23R 4061/4885C5AR1 1061/4885TUBB4A 2209/4885
US-20230109564-A1 METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY MTPN, UTRN, SMN1; SMN2 IL23R 4208/4885C5AR1 1000/4885TUBB4A 3495/4885
US-11376304-B2 Methods and compositions for the prevention and treatment of disease COL2A1, ALPI, COL14A1 IL23R 1209/4885C5AR1 1277/4885TUBB4A 487/4885
US-20250276116-A1 METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION TNNI3, TNNT2, MB IL23R 4785/4885C5AR1 576/4885TUBB4A 2163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback